Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF – Get Free Report) shares were up 69.9% during trading on Tuesday . The company traded as high as $16.00 and last traded at $16.00. Approximately 200 shares were traded during trading, a decline of 50% from the average daily volume of 400 shares. The stock had previously closed at $9.42.
Santhera Pharmaceuticals Stock Up 69.9 %
The firm has a 50 day moving average price of $9.55 and a 200 day moving average price of $10.62.
Santhera Pharmaceuticals Company Profile
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD).
Recommended Stories
- Five stocks we like better than Santhera Pharmaceuticals
- What is the FTSE 100 index?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- How to Short Nasdaq: An Easy-to-Follow Guide
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Expert Stock Trading Psychology Tips
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Santhera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santhera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
